RxDoctor Payments Data

Cynthia Reed, MD

Neurology · Tucson, AZNPI 1588859581

Payments from drug & device makers

$110,798in general payments, 2019–2025

Across 501 payments — averaging $221.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$77K
  • Amneal Pharmaceuticals LLC$30K
  • Acadia Pharmaceuticals Inc$1K
  • Boston Scientific$841
  • MDD US Operations, LLC$638
  • Medtronic$313
  • plus $1K from 10 others

What the payments were for

  • Consulting fees$6,2256%
  • Speaking & faculty fees$77,37870%
  • Travel & lodging$15,16114%
  • Food & beverage$10,67710%
  • Education$1,3581%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$110,798 in reported general payments places this provider in the 80th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$139,219
Medicare patients
120
Services billed
1,994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa182$279,333
NuplazidPimavanserin Tartrate11$98,419
NourianzIstradefylline11$46,471
Carbidopa-Levodopa ErCarbidopa/Levodopa113$8,066
Carbidopa-LevodopaCarbidopa/Levodopa181$7,301
Rasagiline Mesylate39$6,108
AdlarityDonepezil Hcl14$6,041
RivastigmineRivastigmine Tartrate35$2,550
AmantadineAmantadine Hcl23$2,302
Ropinirole Hcl23$1,355
Donepezil Hcl69$1,168
Gabapentin31$1,123
Pramipexole DihydrochloridePramipexole Di-Hcl32$1,009
Quetiapine Fumarate19$740
Memantine Hcl17$583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$29,528$279,333182 claims
Acadia Pharmaceuticals IncNuplazid$1,191$98,41911 claims
Kyowa Kirin, Inc.Nourianz$120$46,47111 claims
Corium, LLCAdlarity$33$6,04114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 388 neurology providers in Arizona.

Other neurology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →